Targeting inflammatory pathway reduces Alzheimer's disease in mice

December 15, 2014, Journal of Clinical Investigation

Alzheimer's disease (AD) is the most common form of dementia and is characterized by the formation of β-amyloid plaques throughout the brain. Proteins known as chemokines regulate inflammation and the immune response. In both patients with AD and mouse AD models, the chemokine CXCL10 is found in high concentrations in the brain and may contribute to AD.

A new study in the Journal of Clinical Investigation indicates that activation of the CXCL10 receptor, CXCR3, contributes to AD pathology. Using a murine model of AD, Michael Heneka and colleagues at the University of Bonn found that mice lacking CXCR3 had reduced β-amyloid plaque formation. Importantly, loss of CXCR3 signaling in AD mice attenuated .

The results of this study suggest that CXCR3 should be explored as a potential therapeutic target for AD.

Explore further: Inflammatory mediator enhances plaque formation in Alzheimer's disease

More information: CXCR3 promotes plaque formation and behavioral deficits in an Alzheimer's disease model, J Clin Invest. DOI: 10.1172/JCI66771

Related Stories

Inflammatory mediator enhances plaque formation in Alzheimer's disease

September 7, 2011
Alzheimer's disease (AD) is a devastating neurodegenerative disorder that causes progressive cognitive impairment and memory loss. Now, a new study published by Cell Press in the September 8 issue of the journal Neuron identifies ...

Drugs targeting blood vessels may be candidates for treating Alzheimer's

March 7, 2013
(Medical Xpress)—University of British Columbia researchers have successfully normalized the production of blood vessels in the brain of mice with Alzheimer's disease (AD) by immunizing them with amyloid beta, a protein ...

Study examines association between small-vessel disease, Alzheimer pathology

May 12, 2014
Cerebral small-vessel disease (SVD) and Alzheimer disease (AD) pathology appear to be associated.

Bilingualism delays Alzheimer manifestation by more than four years

December 1, 2014
A new study at Ghent University has established that the symptoms of Alzheimer disease (AD) manifest themselves about four to five years later in bilinguals as opposed to monolinguals. In bilinguals, the disease onset was ...

'Alzheimer's in a Dish' model induces skin cells into neurons expressing amyloid-beta (w/ Video)

December 5, 2014
The search for a living laboratory model of human neurons in the grip of Alzheimer's disease (AD)—the so-called "Alzheimer's in a dish"—has a new candidate. In work presented at the ASCB/IFCB meeting in Philadelphia, ...

Study links enzyme to Alzheimer's disease

July 21, 2014
Unclogging the body's protein disposal system may improve memory in patients with Alzheimer's disease (AD), according to a study from scientists at Kyungpook National University in Korea published in The Journal of Experimental ...

Recommended for you

Cell therapy could improve brain function for Alzheimer's disease

March 15, 2018
Like a great orchestra, your brain relies on the perfect coordination of many elements to function properly. And if one of those elements is out of sync, it affects the entire ensemble. In Alzheimer's disease, for instance, ...

Physically fit women nearly 90 percent less likely to develop dementia

March 14, 2018
Women with high physical fitness at middle age were nearly 90 percent less likely to develop dementia decades later, compared to women who were moderately fit, according to a study published the March 14, 2018, online issue ...

Poor sleep may heighten Alzheimer's risk

March 12, 2018
(HealthDay)—Older adults who are sleepy during the day might have harmful plaque building in their brain that is a sign of impending Alzheimer's disease, researchers report.

Dementia patients with distorted memories may actually retain key information – researchers say

March 7, 2018
Some memories containing inaccurate information can be beneficial to dementia sufferers because it enables them to retain key information researchers say.

The brain's immune system may be key to new Alzheimer's treatments

March 7, 2018
Sanford Burnham Prebys Medical Research Institute (SBP) researchers have published two new studies in Neuron that describe how TREM2, a receptor found on immune cells in the brain, interacts with toxic amyloid beta proteins ...

Study reveals novel biomarkers for future dementia risk

March 6, 2018
Sudha Seshadri, M.D., founding director of the Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases at UT Health San Antonio, is co-leader and senior author on research announced March 6 that identifies novel ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.